Search

Search Constraints

You searched for: Author/Creator Lees, Charlie W

Search Results

1. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. (2nd September 2021)

2. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Issue 10 (8th June 2020)

3. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Issue 5 (22nd March 2021)

4. Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease. Issue 2 (3rd July 2019)

6. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Issue 6 (17th April 2020)

8. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. (November 2022)

9. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. (April 2022)

10. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts. (5th June 2021)